United Therapeutics Corporation
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from United Therapeutics Corporation's yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales and profit both grew in each of the last 3 years. Steadier than 96% of Healthcare companies in United States.
- Tangible Net Worth Ratio: Of every $100 of net worth, $98 is tangible; the rest is goodwill and other intangibles, often from buying other companies. More tangible than 89% of Healthcare companies in United States.
- Tangible Assets Ratio: Of every $100 the company owns, $99 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. More tangible than 86% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
$110Over the last 3 years, every $100 of reported profit came with $110 of operating cash.
Lower than 77% of Healthcare companies in United States.
Self-Funding Ratio
3.9×Over the last 3 years its own operating cash covered its investment spending (capex) 3.9 times.
Higher than 82% of Healthcare companies in United States.
Cash Locked Ratio
$17For every $100 of sales, $17 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $16 tied up three years earlier.
Less money tied up than 66% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 3/3Sales and profit both grew in each of the last 3 years.
Steadier than 96% of Healthcare companies in United States.
Growth Efficiency Ratio
$49Sales grew 64% in 3 years; of every extra $100 of sales, $49 became extra profit.
Higher than 70% of Healthcare companies in United States.
Asset Productivity Ratio
+64% / +30%In 3 years sales changed by +64% while total assets changed by +30%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
—Data incomplete
Cash Cushion Ratio
—Data incomplete
Tangible Assets Ratio
99%Of every $100 the company owns, $99 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 86% of Healthcare companies in United States.
Tangible Net Worth Ratio
98%Of every $100 of net worth, $98 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 89% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
United Therapeutics Corporation owes $0.11 for every $1 it owns. Net profit rose 12% in the year to Dec 2025, and grew 22% a year on average over 3 years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
20.9Investors pay $20.9 for every $1 of United Therapeutics Corporation's yearly profit, lower than 62% of Healthcare companies in United States.
P/B ratio
3.92The share price is 3.92 times United Therapeutics Corporation's book value per share, higher than 65% of Healthcare companies in United States.
Market cap
$25.1 BThe total market value of all of United Therapeutics Corporation's shares at today's price (share price × number of shares), larger than 94% of Healthcare companies in United States. PosiCap size class: Tito Cap.
Net worth (book value)
$6.4 BWhat United Therapeutics Corporation would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$149.22Net worth divided by the number of shares. The share price of $584.79 is 3.9 times this, which is the P/B above.
Return on equity (ROE)
19.3%United Therapeutics Corporation earned 19.3% on its shareholders' money over the last year, higher than 89% of Healthcare companies in United States.
Owes vs Owns
0.11×United Therapeutics Corporation owes $0.11 for every $1 it owns (low), lower than 85% of Healthcare companies in United States.
Dividend yield
NoneUnited Therapeutics Corporation does not currently pay a dividend.
Revenue growth
+11%Revenue rose 11% in the year to Dec 2025, and grew 18% a year on average over 3 years.
Profit growth
+12%Net profit rose 12% in the year to Dec 2025, and grew 22% a year on average over 3 years.
Profit margin
41.9%United Therapeutics Corporation keeps $42 of every $100 of revenue as net profit.
Cash quality
1.2×Cash from United Therapeutics Corporation's business was 1.2× its reported profit in the year to Dec 2025 — its profit turned into cash.
Interest cover
77.8×United Therapeutics Corporation's operating profit covered its interest costs 77.8 times in the year to Dec 2025.
Questions
What is United Therapeutics Corporation's P/E ratio?
Investors pay $20.9 for every $1 of United Therapeutics Corporation's yearly profit, lower than 62% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For United Therapeutics Corporation: $25.1 B ÷ $6.4 B (30 Jun 2026) = 3.9.
What is United Therapeutics Corporation's return on equity?
United Therapeutics Corporation earned 19.3% on its shareholders' money over the last year, higher than 89% of Healthcare companies in United States.
How much does United Therapeutics Corporation owe compared with what it owns?
United Therapeutics Corporation owes $0.11 for every $1 it owns (low), lower than 85% of Healthcare companies in United States.
Does United Therapeutics Corporation pay a dividend?
No. United Therapeutics Corporation does not currently pay a dividend.
Is United Therapeutics Corporation's revenue growing?
Revenue rose 11% in the year to Dec 2025, and grew 18% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.